RELEASE(重新审视长期抗抑郁药使用):一项在全科实践中开展的三臂实用整群随机对照试验的有效性-实施混合1型方案
该研究为在澳大利亚昆士兰州东南部全科诊所开展的三臂实用整群随机对照试验(有效性-实施混合1型),纳入28家诊所的653例服用抗抑郁药超过1年的成人。诊所按常规照护:RELEASE:RELEASE+为1.5:1:1随机分组,主要结局为12个月时患者自报抗抑郁药使用情况,停药定义为0 mg维持至少2周。研究旨在评估两种多策略干预支持安全停用长期抗抑郁药的有效性、成本效果及实施策略。
要点
- RELEASE和RELEASE+均为支持长期抗抑郁药安全停用的多策略干预。
- 主要结局为12个月时患者自报抗抑郁药使用,停药定义为0 mg维持至少2周。
- 研究同时评估成本效果与实施结局(采纳度和保真度)。
核心结论
- RELEASE研究将产生适用于国际的新知识,涉及两种多策略干预支持安全停用长期抗抑郁药的有效性、成本效果和实施,以改善初级卫生保健和患者结局。
研究设计与样本
- 三臂实用整群随机对照试验,有效性-实施混合1型。
- 地点为澳大利亚昆士兰州东南部的初级照护全科诊所。
- 人群为18岁及以上、服用抗抑郁药超过1年的成人。
- 诊所按常规照护:RELEASE:RELEASE+为1.5:1:1比例随机分组。
- 样本量为来自28家诊所的653例患者。
主要发现
- RELEASE对患者包括循证信息和资源及用药审查邀请;对全科医生包括教育、培训及通过执业管理软件提供的可打印资源。
- RELEASE+包括额外的患者互联网支持和处方支持,包括对全科医生的审计与反馈。
- 主要结局为12个月时患者自报的抗抑郁药使用;停药定义为0 mg抗抑郁药维持至少2周。
- 次要结局包括6个月和12个月时的健康相关生活质量、抗抑郁药副作用、幸福感、撤药症状、情感麻木、对抗抑郁药的信念、抑郁症状和焦虑症状;12个月时抗抑郁药剂量减少75%;诊所层面汇总的抗抑郁药处方及用于成本计算的卫生服务利用。
- 实施评估采用混合方法,包括最多40例患者和初级照护全科医生的访谈、简短电子调查和研究管理数据,以评估实施结局(采纳度和保真度)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many people experience withdrawal symptoms when they attempt to stop antidepressants. Withdrawal symptoms are readily misconstrued for relapse or ongoing need for medication, contributing to long-term use (> 12 months). Long-term antidepressant use is increasing internationally yet is not recommended for most people. Long-term use is associated with adverse effects including weight gain, sexual dysfunction, lethargy, emotional numbing and increased risk of falls and fractures. This study aims to determine the effectiveness of two multi-strategy interventions (RELEASE and RELEASE+) in supporting the safe cessation of long-term antidepressants, estimate cost-effectiveness, and evaluate implementation strategies. METHODS: DESIGN: 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1. SETTING: primary care general practices in southeast Queensland, Australia. POPULATION: adults 18 years or older taking antidepressants for longer than 1 year. Practices will be randomised on a 1.5:1:1 ratio of Usual care:RELEASE:RELEASE+. INTERVENTION: RELEASE for patients includes evidence-based information and resources and an invitation to medication review; RELEASE for GPs includes education, training and printable resources via practice management software. RELEASE+ includes additional internet support for patients and prescribing support including audit and feedback for GPs. OUTCOME MEASURES: the primary outcome is antidepressant use at 12 months self-reported by patients. Cessation is defined as 0 mg antidepressant maintained for at least 2 weeks. SECONDARY OUTCOMES: at 6 and 12 months are health-related quality of life, antidepressant side effects, well-being, withdrawal symptoms, emotional numbing, beliefs about antidepressants, depressive symptoms, and anxiety symptoms; and at 12 months 75% reduction in antidepressant dose; aggregated practice level antidepressant prescribing, and health service utilisation for costs. SAMPLE SIZE: 653 patients from 28 practices. A concurrent evaluation of implementation will be through mixed methods including interviews with up to 40 patients and primary care general practitioners, brief e-surveys, and study administrative data to assess implementation outcomes (adoption and fidelity). DISCUSSION: The RELEASE study will develop new knowledge applicable internationally on the effectiveness, cost-effectiveness, and implementation of two multi-strategy interventions in supporting the safe cessation of long-term antidepressants to improve primary health care and outcomes for patients. TRIAL REGISTRATION: ANZCTR, ACTRN12622001379707p. Registered on 27 October 2022.
引用
- Wallis KA, Donald M, Horowitz M, et al. RELEASE (REdressing Long-tErm Antidepressant uSE): protocol for a 3-arm pragmatic cluster randomised controlled trial effectiveness-implementation hybrid type-1 in general practice. Trials. 2023. PMID: 37770893. doi:10.1186/s13063-023-07646-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。